This unique and exciting new program offers endocrinologists and other diabetes care providers the opportunity to engage in a discussion with a Pulmonary Expert to learn more about the use of EXUBERAŽ (insulin human [rDNA origin]) Inhalation Powder in the treatment of patients with type 1 and type 2 diabetes. Endocrinologists, diabetologists, diabetes educators, and office staff members are encouraged to attend. Each hour-long conference is web-based, so clinicians can participate anywhere there is an Internet connection and phone line. Date Time Location 9/25/2007 6:30 PM Chicago, IL 9/26/2007 6:30 PM Phoenix, AZ 10/4/2007 6:30 PM Birmingham, AL

EXUBERAŽ (insulin human [rDNA origin]) Inhalation Powder is a rapid-acting insulin indicated for the treatment of adults with diabetes mellitus for the control of hyperglycemia. In patients with type 1 diabetes, EXUBERA should be used in regimens that include a longer-acting insulin. In patients with type 2 diabetes, EXUBERA can be used as monotherapy or in combination with oral agents or longer-acting insulins. In clinical trials, treatment with EXUBERA was associated with small, nonprogressive mean declines in pulmonary function relative to comparator treatments. Because of the effect of EXUBERA on pulmonary function, all patients should have pulmonary function tests (eg, spirometry) assessed prior to initiating therapy with EXUBERA, after 6 months of therapy, and annually thereafter, even in the absence of pulmonary symptoms. Assessment of DLco should be considered. EXUBERA is contraindicated in patients who smoke or who have discontinued smoking less than 6 months prior to starting EXUBERA therapy. If a patient starts or resumes smoking, EXUBERA must be discontinued immediately due to the increased risk of hypoglycemia and an alternative treatment must be utilized. EXUBERA is contraindicated in patients with unstable or poorly controlled lung disease, because of wide variations in lung function that could affect the absorption of EXUBERA and increase the risk of hypoglycemia or hyperglycemia. The use of EXUBERA in patients with underlying lung disease, such as asthma or COPD, is not recommended because the safety and efficacy of EXUBERA in this population have not been established. Hypoglycemia is the most commonly reported adverse event of insulin therapy, including EXUBERA. The long-term safety and effectiveness of EXUBERA in pediatric patients have not been established. Please see EXUBERA full prescribing information and EXUBERA Medication Guide Copyright 2007 Pfizer Inc. All rights reserved. Terms of Use Agreement The health information contained herein is provided for educational purposes only. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Privacy Policy Contact Us EXUBERA UPDATE is a promotional educational program sponsored by Pfizer Inc. Medical DecisionPoint / 110 Summit Avenue / Montvale, NJ / 07645 / 201-740-6100